Search
Search Results
-
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
Chimeric antigen receptor (CAR)-T cell therapy is a promising new treatment for cancer that involves genetically modifying a patient’s T-cells to...
-
CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials
BackgroundPancreatic and biliary tract cancers are digestive system tumors with dismal prognosis and limited treatment options. The effectiveness of...
-
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs) specific for CD19 or B cell maturation antigen (BCMA) are...
-
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
The past decade has witnessed ongoing progress in immune therapy to ameliorate human health. As an emerging technique, chimeric antigen receptor...
-
-
Engineering switchable and programmable universal CARs for CAR T therapy
A traditional chimeric antigen receptor (CAR) has a fixed design, and one type of CAR T cells can only target one antigen epitope. This rigid design...
-
Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies
Chimeric antigen receptor T (CAR-T) cell therapy is the novel treatment strategy for hematological malignancies such as acute lymphoblastic leukemia...
-
Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy
CAR-T cell therapy, as a novel immunotherapy approach, has indicated successful results in the treatment of hematological malignancies; however,...
-
Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
In the recent years, using genetically modified T cells has been known as a rapid develo** therapeutic approach due to the heartwarming results of...
-
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
There has been a rapid progress in develo** genetically engineered T cells in recent years both in basic and clinical cancer studies. Chimeric...
-
Next-generation CAR T cells to overcome current drawbacks
As a rapidly emerging treatment in the oncology field, adoptive transfer of autologous, genetically modified chimeric antigen receptor (CAR) T cells...
-
Advances in nano-immunotherapy for hematological malignancies
Hematological malignancies (HMs) encompass a diverse group of blood neoplasms with significant morbidity and mortality. Immunotherapy has emerged as...
-
Challenges and new technologies in adoptive cell therapy
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to the subsequent specific...
-
Programmable synthetic receptors: the next-generation of cell and gene therapies
Cell and gene therapies hold tremendous promise for treating a range of difficult-to-treat diseases. However, concerns over the safety and efficacy...
-
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered...
-
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
The combination of the immunotherapy (i.e., the use of monoclonal antibodies) and the conventional chemotherapy increases the long-term survival of...
-
ImmunoPET for prostate cancer in the PSMA era: do we need other targets?
IntroductionIn recent years, prostate specific membrane antigen (PSMA) has been gaining a crucial role for prostate cancer (PC) management,...
-
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
BackgroundChimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in...
-
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
BackgroundThe therapeutic application of T cells endowing with chimeric antigen receptors (CARs) is faced with “on-target, off-tumor” toxicity...
-
γδ T cells: origin and fate, subsets, diseases and immunotherapy
The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and hyperactivation, highlights the potential of immune...
